Plasma centers test every single donation for HIV. This is a federal requirement, not a voluntary practice. Under FDA regulations, every unit of blood or plasma collected must be screened for specific infectious diseases, including HIV, before it can be used to manufacture any injectable product. There is no exception for frequent donors who tested negative last week.
Every Donation Gets Tested
The FDA’s blood testing rule requires establishments that collect blood and blood components, including source plasma, to test each donation for evidence of infection due to specific communicable disease agents. For HIV, this means your plasma is screened every time you sit in that chair, whether you donate twice a week or once a month. The plasma you gave today gets tested independently from the plasma you gave three days ago.
This per-donation testing is paired with a health screening questionnaire you complete at every visit. The FDA updated its donor eligibility guidance in 2025, shifting to individual risk-based questions that apply the same way to all donors regardless of sex. These questions assess recent behaviors that could increase the chance of HIV transmission. If your answers flag a concern, you’ll be deferred before the needle ever comes out.
Two Layers of Testing
Plasma centers don’t rely on a single test. The FDA recommends a two-pronged approach for each donation. First, an antibody screening test checks whether your immune system has produced antibodies against HIV. This catches infections that have been present long enough for your body to mount a response. Second, a nucleic acid test (NAT) looks directly for the virus’s genetic material in the sample.
NAT is the more sensitive of the two. It can detect HIV roughly 11 to 15 days earlier than antibody testing alone, catching infections during the acute phase when someone is newly infected but hasn’t yet developed detectable antibodies. Before NAT became standard, centers used a separate antigen test to help close that gap. The FDA now considers NAT sensitive enough to replace that older antigen test entirely. These two tests can run at the same time on your sample, so results come back together.
How Accurate These Tests Are
Combined, the screening methods are extremely reliable. A comparative study of antibody-based screening and NAT across thousands of donations found 100% accuracy for HIV detection when both methods were used together, with zero false negatives. The false positive rate for HIV was just 0.01%, meaning that out of 10,000 donations, roughly one might incorrectly flag as reactive when no actual infection exists.
That said, no screening system is perfect in isolation. NAT works best at catching very early infections, while antibody tests are better at confirming established ones. Using both together eliminates virtually all gaps. The remaining sliver of risk comes from the very earliest days of infection, a brief window before even NAT can pick up the virus. That window is estimated at about 5 to 10 days after infection.
What Happens Before You Become a Regular Donor
The plasma industry adds another safety layer on top of per-donation testing through what’s called the Qualified Donor standard, maintained by the Plasma Protein Therapeutics Association. Before you’re considered a qualified donor, you must pass two separate medical screenings and test negative for HIV, hepatitis B, and hepatitis C on two different occasions. Only after both rounds come back clean are you cleared to donate regularly. If you stop donating for six months or longer, you lose that qualified status and have to go through the entire process again.
If a Test Comes Back Reactive
When a donation tests reactive for HIV on the initial screen, the test is repeated. If it comes back reactive again, that donation is immediately quarantined or destroyed. The center also pulls and quarantines any prior donations collected from you that haven’t yet been used. Manufacturers who already received your earlier plasma are notified and must quarantine those units too.
Your donor record is flagged immediately to prevent any further collections. A more specific confirmatory test is then run to determine whether the reactive result represents a true infection or a false alarm. You won’t be contacted about results until this confirmatory testing is complete.
If the confirmatory test is positive, you’ll be counseled that you are likely infected with HIV and permanently deferred from all future blood and plasma donation. If the confirmatory test comes back negative, indicating a false positive, you’ll be told that your screening test was reactive but supplementary testing suggests you’re not infected. Even so, you’ll typically face a temporary deferral of at least eight weeks before you can attempt to requalify. Research on donor reentry programs has found that among donors who initially screen reactive for HIV, roughly 82% turn out to be false positives and can eventually return to donating safely.
Center-Wide Monitoring
Individual testing isn’t the only safeguard. Each plasma center is required to report its overall rates of reactive results for HIV, hepatitis B, and hepatitis C across its entire donor population. These rates are compared against industry averages. If a center’s HIV reactivity rate creeps above an alert threshold, it must implement corrective actions to bring the rate back down. This system catches problems that per-donation testing alone might miss, like a center inadvertently attracting higher-risk donors or falling behind on screening protocols.